| Phase 15 trials |
|
Phase 1
|
NCT06978062 |
Feb 2026 → Sep 2028 expected |
gastroesophageal cancer |
European Organisation for Research and Treatment of Cancer - EORTC |
Not yet recruiting
|
No outcome recorded
|
|
Phase 1
|
NCT05267470 |
Mar 2022 → May 2024 |
non-small cell squamous lung carcinoma |
Amgen |
Terminated
|
No outcome recorded
|
|
Phase 1
|
NCT03343301 |
Nov 2017 → Jan 2019 |
gastric cancer |
Five Prime Therapeutics, Inc. |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT05913115 |
Jun 2017 → Jun 2018 |
gastroesophageal cancer |
Amgen |
Completed
|
No outcome recorded
|
|
Phase 1
|
NCT02318329 |
Nov 2014 → Feb 2019 |
bladder transitional cell carcinoma, gastric cancer |
Five Prime Therapeutics, Inc. |
Completed
|
No outcome recorded
|
| Phase 1/23 trials |
|
Phase 1/2
|
NCT07146919 |
Oct 2025 → Oct 2030 |
cervical cancer, endometrial carcinoma, ovarian cancer |
Centre Leon Berard |
Withdrawn
|
No outcome recorded
|
|
Phase 1/2
|
NCT05325866 |
Sep 2022 → Jan 2026 |
cancer |
Amgen |
Terminated
|
No outcome recorded
|
|
Phase 1/2
|
NCT05322577 |
May 2022 → Nov 2025 overdue |
gastric cancer, gastroesophageal junction adenocarcinoma |
Amgen |
Active not recruiting
|
No outcome recorded
|
| Phase 25 trials |
|
Phase 2
|
NCT07470840 |
Feb 2027 → Feb 2029 expected |
renal cell adenocarcinoma |
Fujian Cancer Hospital |
Not yet recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT06967987 |
Jan 2026 |
gastroesophageal adenocarcinoma |
Institut Cancerologie de l'Ouest |
Withdrawn
|
No outcome recorded
|
|
Phase 2
|
NCT06680622 |
Mar 2025 → Sep 2027 expected |
gastroesophageal adenocarcinoma |
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest |
Active not recruiting
|
No outcome recorded
|
|
Phase 2
|
NCT03694522 |
Sep 2018 → Sep 2020 |
gastric cancer |
Five Prime Therapeutics, Inc. |
Completed
|
No outcome recorded
|
|
Phase 2
|
NCT02213289 |
Jan 2015 → Feb 2020 |
adenocarcinoma |
University of Chicago |
Completed
|
No outcome recorded
|
| Phase 32 trials |
|
Phase 3
|
NCT05111626 |
Mar 2022 → Oct 2025 |
gastric cancer, gastroesophageal junction adenocarcinoma |
Amgen |
Terminated
|
No outcome recorded
|
|
Phase 3
|
NCT05052801 |
Mar 2022 → Jun 2025 |
gastric cancer, gastroesophageal junction adenocarcinoma |
Amgen |
Completed
|
No outcome recorded
|
| Phase not stated1 trial |
| — |
NCT03801278 |
— |
urinary bladder cancer |
Five Prime Therapeutics, Inc. |
No longer available
|
No outcome recorded
|